{"nctId":"NCT01697592","briefTitle":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","startDateStruct":{"date":"2012-10-24","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":585,"armGroups":[{"label":"Omarigliptin 25 mg/Sulfonylureas (SUs) (Phase A+B)","type":"EXPERIMENTAL","interventionNames":["Drug: Omarigliptin"]},{"label":"Omarigliptin 25 mg/Glinides (Phase A+B)","type":"EXPERIMENTAL","interventionNames":["Drug: Omarigliptin"]},{"label":"Omarigliptin 25 mg/biguanides (BGs) (Phase A+B)","type":"EXPERIMENTAL","interventionNames":["Drug: Omarigliptin"]},{"label":"Omarigliptin 25 mg/Thiazolidinediones (TZDs) (Phase A+B)","type":"EXPERIMENTAL","interventionNames":["Drug: Omarigliptin"]},{"label":"Omarigliptin 25 mg/α-GIs (Phase A+B)","type":"EXPERIMENTAL","interventionNames":["Drug: Omarigliptin"]},{"label":"Placebo/SUs (Phase A) → Omarigliptin 25 mg/SUs (Phase B)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Omarigliptin","Drug: Matching placebo to omarigliptin"]},{"label":"Placebo/Glinides (Phase A) → Omarigliptin 25 mg/Gln. (Phase B)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Omarigliptin","Drug: Matching placebo to omarigliptin"]},{"label":"Placebo/BGs (Phase A) → Omarigliptin 25 mg/BGs (Phase B)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Omarigliptin","Drug: Matching placebo to omarigliptin"]},{"label":"Placebo/TZDs (Phase A) → Omarigliptin 25 mg/TZDs (Phase B)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Omarigliptin","Drug: Matching placebo to omarigliptin"]},{"label":"Placebo/α-GIs (Phase A) → Omarigliptin 25 mg/α-GIs (Phase B)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Omarigliptin","Drug: Matching placebo to omarigliptin"]}],"interventions":[{"name":"Omarigliptin","otherNames":[]},{"name":"Matching placebo to omarigliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has type 2 diabetes mellitus\n* Has inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent monotherapy\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus or a history of ketoacidosis\n* History of any of the following medications: Thiazolidinediones (TZD) (for participants whose basal medication is not TZD) and/or insulin within 12 weeks prior to study participation, omarigliptin anytime","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue During Phase A","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. Glycemic rescue criteria were: fasting plasma glucose (FPG) of \\>240 mg/dL, 2 times, (Week 4 to Week 24) and after Week 24, FPG \\>200 mg/dL, 2 times. Glycemic rescue was achieved through up-titration of basal medication (1st rescue) and through the use of metformin or glimepiride (2nd rescue).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":null},{"groupId":"OG001","value":"53.8","spread":null},{"groupId":"OG002","value":"54.5","spread":null},{"groupId":"OG003","value":"60.0","spread":null},{"groupId":"OG004","value":"50.7","spread":null},{"groupId":"OG005","value":"60.3","spread":null},{"groupId":"OG006","value":"52.9","spread":null},{"groupId":"OG007","value":"63.6","spread":null},{"groupId":"OG008","value":"52.9","spread":null},{"groupId":"OG009","value":"53.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue During the Overall Study","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. Glycemic rescue criteria were: fasting plasma glucose (FPG) of \\>240 mg/dL, 2 times, (Week 4 to Week 24) and after Week 24, FPG \\>200 mg/dL, 2 times. Glycemic rescue was achieved through up-titration of basal medication (1st rescue) and through the use of metformin or glimepiride (2nd rescue). These results represent the accrual of events over different treatment intervals: 52 weeks, Omarigliptin (Phase A+B) group, defined as the double-blind period and open-label extension period versus 28 weeks for the placebo switching to Omarigliptin group defined as the open-label extension period only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null},{"groupId":"OG001","value":"75.4","spread":null},{"groupId":"OG002","value":"80.3","spread":null},{"groupId":"OG003","value":"84.6","spread":null},{"groupId":"OG004","value":"68.7","spread":null},{"groupId":"OG005","value":"56.5","spread":null},{"groupId":"OG006","value":"59.4","spread":null},{"groupId":"OG007","value":"66.7","spread":null},{"groupId":"OG008","value":"58.8","spread":null},{"groupId":"OG009","value":"53.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During Phase A","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3.1","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"2.9","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"0","spread":null},{"groupId":"OG009","value":"3.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study","description":"An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure. Glycemic rescue criteria were: fasting plasma glucose (FPG) of \\>240 mg/dL, 2 times, (Week 4 to Week 24) and after Week 24, FPG \\>200 mg/dL, 2 times. Glycemic rescue was achieved through up-titration of basal medication (1st rescue) and through the use of metformin or glimepiride (2nd rescue). These results represent the accrual of events over different treatment intervals: 52 weeks, Omarigliptin (Phase A+B) group, defined as the double-blind period and open-label extension period versus 28 weeks for the placebo switching to Omarigliptin group defined as the open-label extension period only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"4.6","spread":null},{"groupId":"OG002","value":"1.5","spread":null},{"groupId":"OG003","value":"6.2","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"1.6","spread":null},{"groupId":"OG006","value":"0","spread":null},{"groupId":"OG007","value":"0","spread":null},{"groupId":"OG008","value":"2.9","spread":null},{"groupId":"OG009","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24","description":"HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Thus, this change from baseline reflects the Week 24 HbA1c minus the Week 0 HbA1c.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":null},{"groupId":"OG001","value":"-0.68","spread":null},{"groupId":"OG002","value":"-0.94","spread":null},{"groupId":"OG003","value":"-0.88","spread":null},{"groupId":"OG004","value":"-0.74","spread":null},{"groupId":"OG005","value":"0.09","spread":null},{"groupId":"OG006","value":"0.30","spread":null},{"groupId":"OG007","value":"-0.02","spread":null},{"groupId":"OG008","value":"0.28","spread":null},{"groupId":"OG009","value":"0.06","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":126},"commonTop":["Nasopharyngitis","Back pain","Hypoglycaemia","Bronchitis","Constipation"]}}}